Purpose in action – Reproductive medicine and maternal health

Maternal health – a core mission

As a leader in reproductive medicine and maternal health, Ferring’s core mission is to deliver better outcomes at every stage of the reproductive journey – from conception to birth. We believe everyone has the right to quality care to help them build healthy families, wherever they are.

Tackling access to fertility

The Challenge: One in six couples experience fertility issues; yet despite the WHO recognising infertility as both a disease and global public health issue, there is limited funding and coverage for IVF treatment on many national health services and health insurance programmes. Moreover, many policies and laws, for example those linked to marital status or sexual orientation, can prevent people from accessing treatment in their home countries.

The Solution: At Ferring, we believe in everyone’s right to build a family. Every year half a million babies are born as a result of IVF and other assisted reproductive technologies (ART)1. We are committed to building healthy families of every shape and size by developing innovative fertility treatments and working alongside patient communities, healthcare professionals and policy makers to expand access to IVF treatment. In the US, Ferring collaborates with RESOLVE, a US patient group helping to expand access to fertility treatment coverage. In 2019 they helped expand access for over 3 million people seeking to become parents.

Sustained support for research on prematurity

As part of its five-year $10 million commitment, Ferring continues to support the work of March of Dimes through its Prematurity Research Centres, including the first centre in Europe at Imperial College London, which was opened thanks to the Ferring grant. The Prematurity Research Centres are working to find the unknown causes of preterm birth and new
ways to prevent it, and the collaboration aims to accelerate the development of new healthcare solutions that are urgently needed to help babies that are born earlier than expected.
1. European Society of Human Reproduction and Embryology. ART Factsheet 2016. Available at: https://www.eshre.eu/Press-Room/Resources.aspx Last accessed: November 2018

Our part in reducing maternal mortality

The Challenge: PPH, or excessive bleeding after childbirth, is the leading direct cause of maternal mortality worldwide. The vast majority of maternal deaths occur in low and lower-middle income countries where women may not have access to prenatal care, skilled birth attendants or quality treatments.

The Solution: We are committed to reducing PPH as part of our mission to reduce maternal mortality and protect women and families around the world. We believe that every woman should have access to quality care and treatment during pregnancy and childbirth, no matter where she lives. As part
of our commitment to the UN Global Goal on Maternal Health (with the aim to reduce maternal mortality ratio to 70 per 100,000 live births), Ferring is committed to making heat-stable carbetocin, our treatment to prevent PPH, available at an affordable and sustainable price in public sector healthcare facilities in low and lower-middle income countries.

 

India: A young mother smiles with her newborn child
Photo credit: Joni Kabana, Kabana Photography

>

Postpartum haemorrhage (PPH) References (Diagram)
1. Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014;2(6):323-33.

2. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Published 2012. Available at: https://apps.who.int/iris/bitstream/handle/10665/75411/9789241548502_eng.pdf;jsessionid=82A09BE1D5B290A1B68E7400 5D0B3F61. Last accessed: May 2020.

3. World Health Organization. WHO recommendations. Uterotonics for the prevention of postpartum haemorrhage. Published 2018. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf Last accessed: June 2018.

4. Widmer M, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomised controlled trial. Trials 2016;17(1):143.

5. Torloni MR, et al. Quality of Oxytocin Available in Low and Middle-Income Countries: A Systematic Review of the Literature. BJOG 2016;123(13):2076-2086.

6. World Health Organization. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf. Last accessed: May 2020.

7. World Health Organization. Effective Vaccine Management (EVM). Global Data Global Data Analysis 2009-2018. Available at: https://www.who.int/immunization/programmes_systems/supply_ chain/EVM-Global-Data-Analysis-2010- 2018-EN.pdf Last accessed May 2020.

8. Kartoglu U, et al. Stability of oxytocin along the supply chain: A WHO observational study. Biologicals 2017; 50:117-124.

9. Immunization Supply Chain Policy Environment in Uganda. Landscape Analysis and Advocacy Recommendations. Published 2016. Available at: http://www.path.org/publications/files/APP_landscape_analysis_ uganda_rpt.pdf. Last accessed: May 2020